FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

10 Jan 2022 06:00:03 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

06 Dec 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

17 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

04 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

03 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET

28 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

20 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

08 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

02 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

16 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

11 Aug 2021 21:09:48 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

10 Aug 2021 15:24:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

10 Aug 2021 06:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

10 Aug 2021 06:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

04 Aug 2021 06:00:01 By Nasdaq GlobeNewswire